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A bs tr ac t
Background
Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent 
atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic 
and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone 
would reduce major vascular events in high-risk permanent atrial fibrillation.
Methods
We assigned patients who were at least 65 years of age with at least a 6-month history 
of permanent atrial fibrillation and risk factors for major vascular events to receive 
dro ne da rone or placebo. The first coprimary outcome was stroke, myocardial infarc-
tion, systemic embolism, or death from cardiovascular causes. The second coprimary 
outcome was unplanned hospitalization for a cardiovascular cause or death.
Results
After the enrollment of 3236 patients, the study was stopped for safety reasons. The 
first coprimary outcome occurred in 43 patients receiving dro ne da rone and 19 receiv-
ing placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P = 0.002). 
There were 21 deaths from cardiovascular causes in the dro ne da rone group and 10 in 
the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P = 0.046), including death 
from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 
1.06 to 10.00; P = 0.03). Stroke occurred in 23 patients in the dro ne da rone group and 
10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P = 0.02). Hospi-
talization for heart failure occurred in 43 patients in the dronedarone group and 
24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P = 0.02).
Conclusions
Dronedarone increased rates of heart failure, stroke, and death from cardiovascular 
causes in patients with permanent atrial fibrillation who were at risk for major vascular 
events. Our data show that this drug should not be used in such patients. (Funded by 
Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.)
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Dronedarone is a new antiarrhyth-mic agent that is used to restore sinus rhythm and to reduce rates of hospital-
ization for cardiovascular causes in patients with 
intermittent (paroxysmal or persistent) atrial fibril-
lation.1 In ATHENA (A Placebo-Controlled, Double-
Blind, Parallel Arm Trial to Assess the Efficacy of 
Dronedarone 400 mg bid for the Prevention of 
Cardiovascular Hospitalization or Death from any 
Cause in Patients with Atrial Fibrillation/Atrial 
Flutter; ClinicalTrials.gov number, NCT00174785), 
4628 patients with intermittent atrial fibrillation 
were randomly assigned to receive either dro ne-
da rone or placebo. Dronedarone reduced the in-
cidence of the primary outcome of unplanned hos-
pitalization for cardiovascular causes or death. 
Significant reductions in rates of death from car-
diovascular causes, stroke, and hospitalization for 
acute coronary syndrome were also seen.2,3
We decided to evaluate dro ne da rone in patients 
with permanent atrial fibrillation because such 
patients are at high risk for cardiovascular events 
of the type that had been reduced in frequency 
in ATHENA.4,5 The treatment effects of dro ne-
da rone in ATHENA had been seen in most sub-
groups of patients, including those in whom 
permanent atrial fibrillation developed during 
the study,6 which suggested that restoration of 
sinus rhythm may not be the only mechanism of 
benefit associated with this drug. Dronedarone 
has other effects that would be potentially benefi-
cial in patients with permanent atrial fibrillation, 
including slowing of the heart rate during atrial 
fibrillation,7 blood-pressure lowering,2 and adren-
ergic blockade.8,9 In addition, dro ne da rone has 
been shown to suppress ventricular fibrillation in 
animal models10,11 and significantly reduced the 
rate of death from arrhythmia in ATHENA.2
PALLAS (Permanent Atrial Fibrillation Outcome 
Study Using Dronedarone on Top of Standard 
Therapy) was designed to test whether dro ne da-
rone would reduce rates of major vascular events 
or unplanned hospitalization for cardiovascular 
causes in patients with permanent atrial fibrilla-
tion who were at high risk for vascular events.
Me thods
Study Conduct
This study was a randomized, double-blind, 
placebo-controlled trial conducted at 489 sites in 
37 countries. The trial was sponsored by Sanofi-
Aventis and was approved by the ethics commit-
tee at each participating center. It was led by op-
erations and steering committees, whose members 
jointly designed the study and decided to submit 
the manuscript for publication. The Population 
Health Research Institute in Hamilton, Ontario, 
Canada, gathered and analyzed the data. The 
first author wrote the manuscript and vouches 
for the completeness and accuracy of the data 
and the analyses and for the fidelity of this re-
port to the trial protocol, which is available with 
the full text of this article at NEJM.org.
Study Population
We enrolled patients with permanent atrial fibril-
lation or flutter, as documented on electrocardi-
ography performed both within 14 days before 
randomization and 6 or more months before-
hand, who had no evidence of intervening sinus 
rhythm and for whom there was no plan to re-
store sinus rhythm. Eligible patients were at least 
65 years of age with at least one of the following 
risk factors: coronary artery disease; previous 
stroke or transient ischemic attack; symptomatic 
heart failure, which was defined as current New 
York Heart Association class II or III symptoms 
and admission to the hospital for heart failure in 
the previous year (but not in the most recent 
month); a left ventricular ejection fraction of 40% 
or less; peripheral arterial disease; or the combi-
nation of an age of 75 years or older, hyperten-
sion, and diabetes. Major exclusion criteria were 
paroxysmal or persistent atrial fibrillation, use of 
an implantable cardioverter–defibrillator, sus-
tained daytime bradycardia of less than 50 beats 
per minute, or a QT interval corrected for heart 
rate of more than 500 msec (or >530 msec for 
patients with a paced ventricular rhythm). All pa-
tients provided written informed consent.
Study Design
Eligible patients were randomly assigned to receive 
either dro ne da rone (at a dose of 400 mg twice daily) 
or matching placebo. Patients were seen on days 
7 and 30, at 4 months, and every 4 months there-
after. Investigators were advised to use digoxin with 
caution and to monitor serum levels closely. The 
serum level of digoxin was measured on day 7. 
Drugs that are known to prolong the QT interval 
were prohibited. Liver-function tests (measure-
ments of alanine aminotransferase and bilirubin 
levels) were initially performed at each study office 
visit; after a protocol amendment in January 2011, 
these tests were performed monthly in the first 
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6 months and every 2 months for the remainder 
of the first year.
Study Outcomes
The first coprimary outcome was a composite of 
stroke, myocardial infarction, systemic embolism, 
or death from cardiovascular causes. The second 
coprimary outcome was unplanned hospitalization 
for a cardiovascular cause or death. Other out-
comes were death from cardiovascular causes, 
death from arrhythmia, recurrent hospitalization 
for cardiovascular causes, total nights in the hos-
pital for cardiovascular reasons, acute coronary 
syndrome, stroke or systemic embolism, hospi-
talization for heart failure or heart-failure episode 
without hospitalization, and death from any cause. 
Death from cardiovascular causes included deaths 
associated with arrhythmia and those caused by 
heart failure, stroke, and other vascular events. 
Deaths from arrhythmia included unwitnessed 
deaths occurring without symptoms or previous 
hemodynamic decompensation. The diagnosis of 
myocardial infarction was based on a character-
istic rise and fall in cardiac biomarkers with other 
evidence of myocardial ischemia. Stroke was de-
fined as the rapid onset of a new, persistent neu-
rologic deficit attributable to an obstruction in 
cerebral blood flow or hemorrhage and was classi-
fied as ischemic, hemorrhagic, or unspecified. Un-
planned cardiovascular hospitalization was defined 
as nonelective hospitalization for a specified car-
diovascular reason for at least two consecutive 
dates (overnight) or a prolongation of a noncardio-
vascular hospitalization for cardiovascular rea-
sons. Heart-failure episodes (without hospitaliza-
tion) were defined as new or worsening signs or 
symptoms of heart failure requiring intensification 
of heart-failure treatment. All primary and second-
ary outcomes (except heart-failure episodes) were 
adjudicated by an expert committee whose mem-
bers were unaware of study-group assignments.
Statistical Analysis
Assuming an event rate of 4.5% in the control 
group for the first coprimary outcome at 1 year, 
we estimated that an enrollment of 10,800 pa-
tients during a 2-year period with 1 year of addi-
tional follow-up would result in the occurrence of 
844 events. We calculated that this sample size 
would provide a power of 90% to detect a relative 
reduction of 20% in the rate of the first coprimary 
outcome. The primary analysis was based on a 
log-rank test with a two-sided alpha level of 0.05. 
A Holm’s procedure was planned to control for 
multiple statistical comparisons. Student’s t-test 
and the chi-square test were used for the evaluation 
of continuous and categorical variables, respective-
ly. For patients receiving anticoagulation therapy, 
we calculated the time in the therapeutic range us-
ing linear interpolation of values for the interna-
tional normalized ratio (INR) over time. A data 
monitoring committee was charged with recom-
mending termination of the study for safety rea-
sons in the case of clear, consistent, and persistent 
evidence of net harm that overwhelmed benefit. 
One scheduled interim analysis for efficacy was 
planned when 50% of expected events had oc-
curred, on the basis of a modified Haybittle–Peto 
boundary of 4 SD.
R esult s
Patients and Follow-up
Study enrollment began on July 19, 2010. The data 
monitoring committee recommended on July 5, 
2011, that the study be terminated for safety rea-
sons. A date of July 15, 2011, was specified for the 
end of follow-up. A total of 3236 patients had un-
dergone randomization with median follow-up of 
3.5 months. There were two patients without vital-
status assessment at the end of the study. The two 
study groups were well balanced with respect to 
demographic and clinical characteristics (Table 1). 
Patients had a mean age of 75 years, and 69% had 
more than a 2-year history of permanent atrial 
fibrillation or flutter. About two thirds of the pa-
tients had a history of heart failure. A total of 
88% of the patients were receiving rate-control 
medication, one third were receiving digoxin, 
and 84% were receiving a vitamin K antagonist 
(Table 1 in the Supplementary Appendix, avail-
able at NEJM.org).
In the intention-to-treat population, the base-
line electrocardiogram showed atrial fibrillation 
in 98% of the patients and atrial flutter in 2%. At 
the planned 4-month visit, sinus rhythm was 
present in 23 of 621 patients (3.7%) in the dro ne-
da rone group and in 9 of 638 patients (1.4%) in 
the placebo group (P = 0.01). Cardioversion was 
attempted in 4 patients (0.2%) in the dro ne da rone 
group and 2 patients (0.1%) in the placebo group.
The mean (±SD) baseline heart rate was 77±16 
beats per minute in the dro ne da rone group and 
78±16 beats per minute in the placebo group. At 
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the planned 1-month visit, the mean heart rate 
was reduced by 7.6±14.5 beats per minute in the 
dro ne da rone group and was increased by 0.1±14.0 
beats per minute in the placebo group (P<0.001). 
The baseline systolic blood pressure was 133±17 
mm Hg in the two study groups. At 1 month, the 
mean reduction in systolic blood pressure was 
3.5±16.1 mm Hg in the dro ne da rone group and 
1.7±16.1 mm Hg in the placebo group (P = 0.003). 
The mean corrected QT interval (Bazett’s formu-
la) was 426±40 msec in the dro ne da rone group 
and 425±40 msec in the placebo group at base-
line; at 1 month, the mean increase was 8±40 msec 
in the dro ne da rone group and 2±38 msec in the 
placebo group (P<0.001).
For patients receiving digoxin, the mean serum 
digoxin concentration on day 7 was 1.2±0.8 ng 
per milliliter for 447 patients in the dro ne da rone 
group and 0.9±0.6 ng per milliliter for 438 pa-
tients in the placebo group (P <0.001). Study medi-
cation was permanently discontinued prematurely 
in 348 patients (21%) in the dro ne da rone group 
and in 178 patients (11%) in the placebo group 
(P<0.001). For patients receiving a vitamin K an-
tagonist, the mean time in the therapeutic range 
(INR, 2.0 to 3.0) was 55.6% in the dro ne da rone 
group and 58.6% in the placebo group (P = 0.02).
Outcomes
The first coprimary outcome occurred in 43 pa-
tients receiving dro ne da rone and 19 patients re-
ceiving placebo (hazard ratio in the dro ne da rone 
group, 2.29; 95% confidence interval [CI], 1.34 to 
3.94; P = 0.002) (Table 2 and Fig. 1). The second 
coprimary outcome occurred in 127 patients re-
ceiving dro ne da rone and 67 patients receiving 
placebo (hazard ratio, 1.95; 95% CI, 1.45 to 2.62; 
P<0.001) (Fig. 2). There were 25 deaths in the dro-
ne da rone group and 13 in the placebo group (haz-
ard ratio, 1.94; 95% CI, 0.99 to 3.79; P = 0.049). 
There were 21 deaths from cardiovascular causes 
in the dro ne da rone group and 10 in the placebo 
group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; 
P = 0.046), including those associated with ar-
rhythmia in 13 patients receiving dro ne da rone 
and 4 patients receiving placebo (hazard ratio, 
3.26; 95% CI, 1.06 to 10.00; P = 0.03). Stroke oc-
curred in 23 patients in the dro ne da rone group 
and 10 in the placebo group (hazard ratio, 2.32; 
95% CI, 1.11 to 4.88; P = 0.02).
Unplanned hospitalization for cardiovascular 
causes occurred in 113 patients receiving dro ne-
da rone and 59 patients receiving placebo (hazard 
ratio, 1.97; 95% CI, 1.44 to 2.70; P<0.001). Hospi-
talization for heart failure occurred in 43 patients 
in the dro ne da rone group and 24 in the placebo 
group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Dronedarone
(N = 1619)
Placebo
(N = 1617)
Age
Mean — yr 75.0±5.9 75.0±5.9
65 to <75 yr — no. (%) 783 (48.4) 779 (48.2)
≥75 yr — no. (%) 836 (51.6) 838 (51.8)
Male sex — no. (%) 1051 (64.9) 1040 (64.3)
Heart rate — bpm 77±16 78±16
Systolic blood pressure — mm Hg 133±17 133±17
Inclusion risk criteria — no. (%)
Coronary artery disease 661 (40.8) 666 (41.2)
Symptomatic heart failure† 233 (14.4) 240 (14.8)
Left ventricular ejection fraction ≤40% 345 (21.3) 335 (20.7)
Previous stroke or transient ischemic attack 436 (26.9) 458 (28.3)
Peripheral arterial disease 187 (11.6) 213 (13.2)
Age ≥75 yr plus hypertension and diabetes 294 (18.2) 276 (17.1)
CHADS2 score‡
Mean 2.8±1.2 2.9±1.2
≥2 — no. (%) 1427 (88.1) 1444 (89.3)
Duration of permanent atrial fibrillation >2 yr 
— no. (%)
1119 (69.1) 1124 (69.5)
Heart failure — no. (%)
No history 512 (31.6) 535 (33.1)
New York Heart Association class I 234 (14.5) 209 (12.9)
New York Heart Association class II 732 (45.2) 749 (46.3)
New York Heart Association class III 141 (8.7) 124 (7.7)
Other risk factors
Previous myocardial infarction 392 (24.2) 420 (26.0)
Prior coronary-artery bypass grafting 236 (14.6) 206 (12.7)
Permanent pacemaker 229 (14.1) 218 (13.5)
Hypertension 1352 (83.5) 1385 (85.7)
Diabetes mellitus 573 (35.4) 598 (37.0)
* Plus–minus values are means ±SD. There were no significant differences be-
tween the two study groups.
† Symptomatic heart failure was defined as current New York Heart Association 
class II or III symptoms and hospitalization for heart failure in the previous 
year (but not in the most recent month).
‡ CHADS2 is a risk-prediction score ranging from 0 to 6 that gives 1 point each 
for congestive heart failure, hypertension, age of 75 years or older, and diabetes 
and 2 points for either stroke or transient ischemic attack. Data were missing 
for one patient in each study group.
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P = 0.02). Hospitalization for heart failure or a 
heart-failure episode occurred in 115 patients 
receiving dro ne da rone and 55 receiving placebo 
(hazard ratio, 2.16; 95% CI, 1.57 to 2.98; P<0.001).
Adverse Events
The most common adverse events were diarrhea, 
asthenic condition, nausea and vomiting, dizziness, 
dyspnea, and bradycardia. An elevation of alanine 
aminotransferase of more than three times the 
upper limit of the normal range occurred in 23 of 
1574 (1.5%) patients receiving dro ne da rone and 
in 9 of 1589 (0.6%) receiving placebo (P = 0.013) 
(Table 3).
Subgroup Analyses
To assess the consistency of the effects of dro ne da-
rone on the two coprimary composite outcomes, 
prespecified and ad hoc subgroup analyses were 
performed according to baseline characteristics 
(Fig. 1 and 2 in the Supplementary Appendix). The 
effects of dro ne da rone were highly consistent 
across subgroups. For the second coprimary out-
come of unplanned hospitalization for cardiovas-
cular causes or death, there was one significant 
interaction: as compared with patients without 
diabetes, there was a relatively greater risk asso-
ciated with dro ne da rone in patients with diabetes 
(P = 0.03 for interaction). The risk associated with 
dro ne da rone was consistent for both primary 
outcomes and for hospitalization for heart fail-
ure, regardless of whether the left ventricular ejec-
tion fraction was 40% or lower or above 40% or 
whether patients had New York Heart Association 
class II or III symptoms.
Discussion
In this study, among patients with permanent atrial 
fibrillation and additional cardiovascular risk fac-
tors who received dro ne da rone, we found a highly 
significant doubling in the rate of the first com-
posite coprimary outcome (stroke, myocardial in-
farction, systemic embolism, or death from car-
Table 2. Study Outcomes.*
Outcome Dronedarone Placebo
Hazard Ratio
(95% CI)† P Value
No. of 
Events
Rate/100 
Patient-Yr
No. of 
Events
Rate/100 
Patient-Yr
First coprimary outcome 43 8.2 19 3.6 2.29 (1.34–3.94) 0.002
Second coprimary outcome 127 25.3 67 12.9 1.95 (1.45–2.62) <0.001
Death
From any cause 25 4.7 13 2.4 1.94 (0.99–3.79) 0.049
From cardiovascular causes 21 4.0 10 1.9 2.11 (1.00–4.49) 0.046
From arrhythmia 13 2.5 4 0.8 3.26 (1.06–10.0) 0.03
Stroke
Any‡ 23 4.4 10 1.9 2.32 (1.11–4.88) 0.02
Ischemic 18 3.4 9 1.7 2.01 (0.90–4.48) 0.08
Systemic embolism 1 0.2 0 0.0 NA NA
Myocardial infarction or unstable angina 15 2.9 8 1.5 1.89 (0.80–4.45) 0.14
Myocardial infarction 3 0.6 2 0.4 1.54 (0.26–9.21) 0.63
Unplanned hospitalization for cardiovas-
cular causes
113 22.5 59 11.4 1.97 (1.44–2.70) <0.001
Hospitalization for heart failure 43 8.3 24 4.6 1.81 (1.10–2.99) 0.02
Heart-failure episode or hospitalization§ 115 23.2 55 10.7 2.16 (1.57–2.98) <0.001
* The first coprimary outcome was a composite of stroke, myocardial infarction, systemic embolism, or death from car-
diovascular causes. The second coprimary outcome was a composite of unplanned hospitalization for cardiovascular 
causes or death. NA denotes not applicable.
† Hazard ratios are for the comparison between the dronedarone group and the placebo group.
‡ The types of five strokes (four in the dronedarone group and one in the placebo group) were not specified, and one 
stroke in the dronedarone group was hemorrhagic.
§ This category includes two patients who died from reported heart failure.
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diovascular causes). This increase was driven by 
increased rates of stroke and death from cardio-
vascular causes, with myocardial infarction and 
systemic embolism occurring at very low rates. We 
also found an increase in rates of heart failure in 
the dro ne da rone group. The increased rates of 
stroke, death from cardiovascular causes, and heart 
failure explain, to a considerable extent, the highly 
significant near doubling in the rate of the second 
coprimary outcome (unplanned hospitalization 
for cardiovascular causes or death).
The early trial termination markedly reduced 
the statistical power of the study. Early termination 
also increases uncertainty about the interpretation 
of the P values, and the point estimate of the haz-
ard ratio is potentially biased away from the null. 
Despite these limitations, however, the assessment 
of net harm from dro ne da rone in patients with 
permanent atrial fibrillation who are at high risk 
appears to be sound.
In our study after 1 month, patients receiving 
dro ne da rone had significant net reductions of 
8 beats per minute in heart rate and reductions of 
3.5 mm Hg in systolic blood pressure. These 
physiological effects did not translate into reduc-
tions in rates of heart failure and other events, 
either because the changes were too small or be-
cause there were other effects that concurrently 
increased the risk. In dogs with healed myocardial 
infarction, dro ne da rone did not reduce measures 
of myocardial contractile function,12 nor did it re-
duce the left ventricular ejection fraction in pa-
tients with compensated heart failure and an 
ejection fraction of less than 30%.13 However, 
dro ne da rone affects the inward sodium channels 
in the cardiac-cell membrane,14,15 and other drugs 
with this property do reduce left ventricular con-
tractility.16 In ANDROMEDA (Antiarrhythmic Trial 
with Dro ne da rone in Moderate to Severe CHF 
Evaluating Morbidity Decrease, NCT00543699) in-
volving 627 patients with heart failure and severe 
left ventricular systolic dysfunction,17 dro ne da rone 
increased mortality, an effect that was largely at-
tributed to heart failure and that suggested a nega-
tive inotropic effect of dro ne da rone. However, in 
ATHENA, there was a consistent decrease in rates 
of hospitalization for heart failure in patients with 
heart failure.18
In our study, the increased risk of stroke in 
patients receiving dro ne da rone is unexplained. 
In ATHENA, there was a reduction in the rate of 
stroke2 among patients receiving dro ne da rone, a 
finding that could be related to the prevention of 
recurrence of atrial fibrillation. Dronedarone in-
teracts minimally with vitamin K antagonists,19 
and in our study, the time in the therapeutic INR 
range was significantly lower among patients re-
ceiving dro ne da rone. However, this effect appears 
to be too small to explain the large increase in the 
rate of stroke.
The increase in the rate of death from cardio-
vascular causes was mostly due to a substantial 
increase in the rate of death associated with ar-
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Figure 1. Risk of the First Coprimary Outcome (Stroke, Myocardial Infarction, 
Systemic Embolism, or Death from Cardiovascular Causes).
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Figure 2. Risk of the Second Coprimary Outcome (Unplanned Hospitalization 
for Cardiovascular Causes or Death).
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rhythmia. This finding was surprising, since dro-
ne da rone had not been associated with proar-
rhythmic toxic effects in previous studies in 
animals,10,11 and in ATHENA, dro ne da rone sig-
nificantly reduced the tertiary outcome of death 
from arrhythmia by 45%.2 However, dro ne da rone 
is a cardiac multiple ion-channel blocker,14,15 and 
other cardiac ion-channel–blocking antiarrhyth-
mic drugs have been shown to increase rates of 
death associated with arrhythmia.20,21
Dronedarone increases the serum digoxin level 
through a P-glycoprotein interaction,19 and digoxin 
toxicity is associated with life-threatening ven-
tricular arrhythmia and conduction block.22 In 
our study, almost one third of patients were re-
ceiving digoxin, and in these patients, dro ne da-
rone increased digoxin serum levels by 33%, from 
0.9 to 1.2 ng per milliliter. A post hoc analysis 
of the Digitalis Investigation Group (DIG) trial 
(NCT00000476)23 reported that a serum digoxin 
level of more than 1.2 ng per milliliter was associ-
ated with a significant increase in death from 
cardiovascular causes not related to heart failure. 
It is therefore possible that digoxin toxicity induced 
by dro ne da rone played a role in the increased car-
diovascular mortality.
Our findings regarding the effects of dro ne da-
rone among patients with atrial fibrillation dif-
fered starkly from the results in ATHENA. In that 
trial, there was a highly significant reduction in 
the primary outcome of unplanned hospitalization 
for cardiovascular causes or death and significant 
Table 3. Adverse Events and Abnormalities on Laboratory Testing.*
Event
Dronedarone
(N = 1614)
Placebo
(N = 1609) P Value
number (percent)
Any adverse event 797 (49.4) 600 (37.3) <0.001
Any serious adverse event 113 (7.0) 77 (4.8) 0.008
Any adverse event leading to treatment discontinuation 212 (13.1) 80 (5.0) <0.001
Any reported liver-function abnormality 61 (3.8) 28 (1.7) <0.001
Asthenic conditions (asthenia, fatigue) 89 (5.5) 46 (2.9) <0.001
Breathing abnormalities (dyspnea) 75 (4.6) 36 (2.2) <0.001
Diarrhea 101 (6.3) 38 (2.4) <0.001
Electrocardiographic investigations (QT prolonged) 33 (2.0) 16 (1.0) 0.02
Edema (peripheral edema) 60 (3.7) 29 (1.8) <0.001
Gastrointestinal or abdominal pain 33 (2.0) 15 (0.9) 0.009
Increased creatinine level 49 (3.0) 11 (0.7) <0.001
Lower respiratory tract or lung infection 40 (2.5) 42 (2.6) 0.81
Nausea or vomiting 76 (4.7) 28 (1.7) <0.001
Neurologic signs or symptoms (dizziness) 76 (4.7) 39 (2.4) <0.001
Rate and rhythm disorders (bradycardia) 67 (4.2) 19 (1.2) <0.001
Renal failure or impairment 35 (2.2) 12 (0.7) <0.001
Upper respiratory tract infection 34 (2.1) 35 (2.2) 0.89
Alanine aminotransferase and bilirubin†
Alanine aminotransferase >3× ULN 23 (1.5) 9 (0.6) 0.013
Alanine aminotransferase >3× ULN and bilirubin  
>2× ULN
1 (<0.1)‡ 0 NA
* Listed are adverse events and serious adverse events that occurred in patients receiving at least one dose of a study drug 
with a reported frequency of 2% or more in each study group. The preferred term is provided for explanatory  purposes in 
parentheses when one preferred term predominated. NA denotes not applicable, and ULN upper limit of the normal range.
† Alanine aminotransferase was measured in 1574 patients in the dronedarone group and in 1589 in the placebo group; 
the combination of alanine aminotransferase and bilirubin was measured in 1571 patients in the dronedarone group 
and in 1589 in the placebo group.
‡ One patient received the diagnosis of biliary stasis that was not considered to be related to dronedarone.
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reductions in the rates of death from cardiovas-
cular causes and stroke, without a significant in-
crease in the rate of heart failure.2,18 There are 
important differences between our study and 
ATHENA. Patients in our study were older and 
were more likely to have a history of heart fail-
ure, coronary artery disease, or stroke. Droneda-
rone also increased cardiovascular mortality in 
patients enrolled in ANDROMEDA19 who were also 
at high risk for vascular events owing to severe 
systolic dysfunction and recent hospitalization 
for heart failure. However, there were some high-
risk patients in ATHENA, and subgroup analyses 
in that study did not indicate a hazard for dro ne-
da rone in those patients.2,18 Moreover, subgroup 
analyses in our study did not suggest that the 
risks associated with dro ne da rone were concen-
trated among high-risk patients. Nonetheless, it is 
reasonable to conclude that dro ne da rone should be 
avoided in patients with heart failure and other 
advanced cardiovascular disease, particularly when 
they also have permanent atrial fibrillation.
An important difference between the two stud-
ies is that atrial fibrillation was permanent in our 
study and paroxysmal or persistent in ATHENA. 
Once permanent atrial fibrillation becomes long-
standing, it is unlikely to revert to sinus rhythm. 
We observed a very low rate of conversion to sinus 
rhythm among patients receiving dro ne da rone (a 
net difference of 2% of patients at 4 months). On 
the other hand, in ATHENA, dro ne da rone signifi-
cantly reduced the median time to recurrence of 
atrial fibrillation by 25% and reduced the need for 
electrical cardioversion by 32%.24 Maintenance 
of sinus rhythm could partly underlie reductions 
in stroke and in other vascular events observed in 
ATHENA. We can hypothesize that for high-risk 
patients with permanent atrial fibrillation, direct 
and indirect toxic effects of dro ne da rone are not 
offset by the benefit of maintaining sinus rhythm, 
and any benefits that might occur from heart-rate 
slowing, blood-pressure reduction, antiadrenergic 
action, and suppression of ventricular arrhythmia 
were either small or nonexistent.
In summary, dro ne da rone increased the rates of 
stroke, heart failure, and death from cardiovascular 
causes in patients with permanent atrial fibrillation 
and risk factors for vascular events. Our data show 
that dronedarone is hazardous in such patients.
Supported by Sanofi-Aventis.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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